Ling Gao

R. Doebele, E. Berge, D. Camidge, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Study Evaluating the Effect of Concomitant Ramucirumab on the Pharmacokinetics of Docetaxel in Patients with Advanced Solid Tumors

David C. Smith, D. Shepard, Ling Gao, 2016 .

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

C. Tournigand, J. Ajani, M. Shah, 2022, Cancers.

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Keunchil Park, D. Planchard, L. Paz-Ares, 2020, Clinical Cancer Research.

A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

R. Sullivan, K. Flaherty, G. Shapiro, 2019, Molecular Cancer Therapeutics.

Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors

P. LoRusso, F. Braiteh, D. Shepard, 2016, Cancer Chemotherapy and Pharmacology.

Phase II study evaluating the effect of concomitant ramucirumab (RAM) on the pharmacokinetics (PK) of irinotecan (IRI) and its metabolite SN-38 when coadministered with folinic acid (FA) and 5-fluorouracil (5-FU) (FOLFIRI) in patients (pts) with advanced malignant solid tumors.

P. LoRusso, F. Braiteh, D. Shepard, 2015 .

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.

David C. Smith, L. Chow, D. Shepard, 2014 .

Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.

A. Ohtsu, Ling Gao, T. Yoshino, 2015, Anticancer research.

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

L. Zender, R. Herbst, C. Fuchs, 2020, Cancers.

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

W. Gradishar, J. Sparano, P. Ward, 2017, The oncologist.

Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.

H. Iwata, N. Masuda, Ling Gao, 2016, Japanese journal of clinical oncology.

Head-to-head comparison of Sonazoid and SonoVue in the diagnosis of hepatocellular carcinoma for patients at high risk

Jiayan Huang, Q. Lu, Ling Gao, 2023, Frontiers in Oncology.

Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.

G. Naik, Erin K. Wagner, L. Eberst, 2020, The oncologist.

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

P. Philip, S. Alberts, Z. Wainberg, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.

T. Satoh, Ling Gao, M. Gotoh, 2015, The oncologist.

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

M. Kudo, A. El-Khoueiry, B. Sangro, 2023, Clinical and translational science.